Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Proffered Paper 1 - NSCLC, metastatic

4884 - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

Date

27 Sep 2019

Session

Proffered Paper 1 - NSCLC, metastatic

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Laura Chow

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

L.Q. Chow1, F. Barlesi2, E.M. Bertino3, M.J. van den Bent4, H. Wakelee5, P.Y. Wen6, C. Chiu7, S. Orlov8, M. Majem9, R. Chiari10, M. McKeage11, C. Yu12, F.K. Hurtado13, P. Cazorla Arratia14, Y. Song15, F. Branle16, M. Shi14, D. Kim17

Author affiliations

  • 1 Dept. Of Oncology, University of Washington, 98109-4405 - Seattle/US
  • 2 Dept. Of Multidisciplinary Oncology And Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEDEX 20 - Marseille/FR
  • 3 Dept. Of Internal Medicine - Medical Oncology, The Ohio State University Medical Center, 43210 - Columbus/US
  • 4 Dept. Of Neurologie, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL
  • 5 Dept. Of Medicine/oncology, Stanford University, 94305 - Stanford/US
  • 6 Dept. Of Medical Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 7 Dept. Of Chest Medicine, Taipei Veterans General Hospital, 11217 - Taipei City/TW
  • 8 Dept. Of Oncology, State Pavlov Medical University, 197022 - Saint-Petersburg/RU
  • 9 Dept. Of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 10 Dept. Of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, 06132 - Perugia/IT
  • 11 Dept. Of Pharmacology And Clinical Pharmacology, And Auckland Cancer Society Research Centre, University of Auckland, 1142 - Auckland/NZ
  • 12 Dept. Of Internal Medicine, National Taiwan University Hospital, 10002 - Taipei/TW
  • 13 Dept. Of Translational Medicine, Novartis Institutes for Biomedical Research, 07936 - East Hanover/US
  • 14 Dept. Of Clinical Development, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 15 Dept. Of Biostatistics, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 16 Dept. Of Drug Development, Novartis AG, 4002 - Basel/CH
  • 17 Dept. Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 4884

Background

Ceritinib is approved for the treatment of pts with metastatic ALK+ NSCLC. In previous studies (ASCEND-1 to 5), ceritinib was highly active in ALK+ NSCLC pts with reported intracranial responses in pts with measurable baseline brain lesions. ASCEND-7 (NCT02336451) was designed to specifically study intracranial effects of ceritinib and we report here efficacy and safety in pts with ALK+ NSCLC metastatic to the brain (Arms 1-4).

Methods

Eligible pts had, WHO performance status 0-2, ALK + (FISH) NSCLC, with active brain metastases (BM) either newly diagnosed or progressive, and ≥1 extracranial measurable lesion using RECIST v1.1. Pts may have been pretreated with chemotherapy and/or crizotinib (ALK inhibitor [ALKi]). Pts were assigned to arms 1 to 4 depending on prior treatment (refer to below table). Primary endpoint was investigator assessed whole body overall response rate (CR or PR) and key secondary endpoint was investigator assessed disease control rate (CR or PR or SD). Intracranial responses and extracranial responses were assessed using modified RECIST 1.1 and RECIST 1.1, respectively.

Results

As of 6-Feb-2019, 138 pts were treated in Arms 1-4 (Arm 1: 42; Arm 2: 40; Arm 3: 12; Arm 4: 44), and all the pts discontinued the treatment. Median follow-up for whole body progression free survival was 5.49 months across Arm 1-4. Efficacy endpoints by investigator assessment are reported in the below Table. Most common AEs (>50% all grades in any of the Arms 1-4) regardless of causality were diarrhoea, nausea, ALT increased, vomiting, AST increased, decreased appetite. Majority of these AEs was grade 1/2.Table:

1478O Overall efficacy

Arm 1 (prior brain radiotherapy and prior ALKi) N = 42Arm 2 (no prior brain radiotherapy and prior ALKi) N = 40Arm 3 (prior brain radiotherapy and no prior ALKi) N = 12Arm 4 (no prior brain radiotherapy and no prior ALKi) N = 44
Whole body efficacy (RECIST v1.1) ORR, % [95% CI] DCR, % [95% CI] 35.7 [21.6, 52.0] 66.7 [50.5, 80.4] 30.0 [16.6, 46.5] 82.5 [67.2, 92.7] 50.0 [21.1, 78.9] 66.7 [34.9, 90.1] 59.1 [43.2, 73.7] 70.5 [54.8, 83.2]
Whole body efficacy (RECIST v1.1) Median DOR, months [95% CI] Estimated 6-month event-free probability, % [95% CI]L‡ = 15 10. 8 [4.1, NE] 64.6 [34.7, 83.5]L‡ = 12 12.8 [3.7, 17.3] 74.1 [39.1, 90.9]L‡ = 6 NE [11.7, NE] 100 [100, 100]L‡ = 26 9.2 [7.3, 23.9] 72.7 [51.1, 86.0]
Whole body efficacy (RECIST v1.1) Median PFS, months [95% CI] Estimated 6-month event-free probability, % [95% CI] 7.2 [3.3, 10.9] 58.7 (41.6, 72.4) 5.6 [3.6, 9.2] 44.7 [28.5, 59.5] NE [1.0, NE] 66.7 [33.7, 86.0] 7.9 [5.5, 9.4] 63.4 [46.8, 76.1]
Intracranial response* (modified RECIST v1.1†) ORR, % [95% CI] DCR, % [95% CI]M = 28 39.3 [21.5, 59.4] 75.0 [55.1, 89.3]M = 29 27.6 [12.7, 47.2] 82.8 [64.2, 94.2]M = 7 28.6 [3.7, 71.0] 85.7 [42.1, 99.6]M = 33 51.5 [33.5, 69.2] 75.8 [57.7, 88.9]
Intracranial response* (modified RECIST v1.1†) Median DOR, months [95% CI] Estimated 6-month event-free probability, % (95% CI)L‡ = 11 9.2 [3.7, NE] 66.7 [28.2, 87.8]L‡ = 8 10.1 [3.8, 17.3] 62.5 [22.9, 86.1]L‡ = 2 NE 100 [100, 100]L‡ = 17 7.5 [5.6, 11.2] 70.6 [43.1, 86.6]
Extracranial response (RECIST v1.1) ORR, % [95% CI] DCR, % [95% CI] 31.0 [17.6, 47.1] 69.0 [52.9, 82.4] 42.5 [27.0, 59.1] 92.5 [79.6, 98.4] 41.7 [15.2, 72.3] 66.7 [34.9, 90.1] 61.4 [45.5, 75.6] 72.7 [57.2, 85.0]
Median OS, months [95% CI] Estimated 12-month event-free probability, % [95% CI]24.0 [12.6, NE] 67.4 [50.4, 79.6]NE [16.2, NE] 72.9 [55.5, 84.5]NE [1.0, NE] 75.0 [40.8, 91.2]NE [26.5, NE] 77.9 [61.8, 87.9]
*

In patients with measurable brain metastases at baseline. †The usual criteria to select target lesions will be used but a maximum five target lesions located in the brain can be selected at baseline and evaluated at each assessment time point. ‡L is the number of patients included in the duration of response analysis. M, number of patients with measurable brain metastases at baseline DCR, disease control rate; DOR, duration of response; NE, not estimable ORR, overall response rate; OS, overall survival; PFS, progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors

Conclusions

Efficacy of ceritinib, either in pts with or without a prior exposure to crizotinib, as reported in other studies, is confirmed in this study where only pts with active brain metastases were eligible. Safety profile of ceritinib in these pts remain consistent to what was reported earlier.

Clinical trial identification

NCT02336451.

Editorial acknowledgement

Shiva Krishna Rachamadugu, Novartis Healthcare Pvt Ltd, Hyderabad, India.

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.

Funding

Novartis Pharmaceuticals Corporation.

Disclosure

L.Q. Chow: Advisory / Consultancy, Consultation Honoraria/Review panel: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Lilly/Imclone; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca/MedImmune ; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Incyte; Advisory / Consultancy: Takeda; Research grant / Funding (institution): VentiRx; Advisory / Consultancy: Sanofi-Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution): Dynavax; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy: Synthorx; Research grant / Funding (institution): Alkermes. F. Barlesi: Honoraria (self), Research grant / Funding (institution): AstraZeneca, Bayer; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Boehringer–Ingelheim; Honoraria (self), Research grant / Funding (institution): Eli Lilly Oncology; Honoraria (self), Research grant / Funding (institution): F. Hoffmann–La Roche Ltd; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Merck; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Pierre Fabre; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Takeda; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): ACEA; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): MedImmune and Sanofi-Aventis; Non-remunerated activity/ies: Principal Investigator for AstraZeneca, BMS, Merck, Pierre Fabre and F. Hoffmann-La Roche, Ltd, sponsored trials (or ISR). E.M. Bertino: Advisory / Consultancy: Takeda; Speaker Bureau / Expert testimony: Pfizer. M.J. van den Bent: Honoraria (self): Celgene, Agios, Boehringer, BMS, AbbVie ; Research grant / Funding (institution): AbbVie. H. Wakelee: Honoraria (self): Novartis, AstraZeneca; Advisory / Consultancy, NOT compensated: Merck, Takeda, Genentech/Roche: AstraZeneca, Xcovery, Janssen; Research grant / Funding (institution): ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bayer (under Suki and not me), BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, Xcovery; Travel / Accommodation / Expenses: AstraZeneca; Officer / Board of Directors: International Association for the Study of Lung Cancer (IASLC). P.Y. Wen: Advisory / Consultancy: Agios, AstraZeneca, Beigene, Eli Lilly, Genentech/Roche, Karyopharm, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Sanofi-Aventis, VBI Vaccines, Tocagen; Speaker Bureau / Expert testimony: Merck, Prime Oncology; Research grant / Funding (institution): Agios, AstraZeneca, Beigene, Eli Lilly, Genentech/Roche, Karyopharm, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Sanofi-Aventis, VBI Vaccines. C. Chiu: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, and Takeda. M. Majem: Advisory / Consultancy: Roche, MSD, AstraZeneca, Boehringer, Tesaro, Takeda, Pierre Fabre; Speaker Bureau / Expert testimony: Roche, BMS, MSD, AstraZeneca, Boehringer Hellsin, Pierre Fabre, Amgen; Research grant / Funding (self): BMS; Travel / Accommodation / Expenses: BMS, MSD, AstraZeneca, Lilly. R. Chiari: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, Roche, and Takeda. M. McKeage: Advisory / Consultancy: Novartis, Pfizer; Research grant / Funding (institution): Novartis, Pfizer, Roche. C. Yu: Honoraria (self): Roche, AstraZeneca, Ono pharma, Boehringer Ingelheim ; Advisory / Consultancy: Roche, AstraZeneca, Ono pharma, Boehringer Ingelheim. F.K. Hurtado: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. P. Cazorla Arratia: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. Y. Song: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. F. Branle: Honoraria (self), Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. M. Shi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. D. Kim: Research grant / Funding (institution): Alpha Biopharma, AstraZeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.